Neuromyelitis optica

Devic's disease
Classification and external resources
Specialty neurology
ICD-10 G36.0
ICD-9-CM 341.0
DiseasesDB 29470
MeSH D009471

Neuromyelitis optica (NMO), also known as Devic's disease or Devic's syndrome, is a heterogeneous condition consisting of the simultaneous inflammation and demyelination of the optic nerve (optic neuritis) and the spinal cord (myelitis). It can be monophasic or recurrent.

Currently at least two different causes are proposed based on the presence of autoantibodies against AQP4. AQP4+ NMO is currently considered an autoimmune disease (autoimmune astrocytopathy,[1] or autoimmune astrocytic channelopathy) in which a person's own immune system attacks the astrocytes of the optic nerves and spinal cord. The cause of the AQP4- variants is unknown.

Although inflammation may also affect the brain, the lesions are different from those observed in the related condition, multiple sclerosis.[2] Spinal cord lesions lead to varying degrees of weakness or paralysis in the legs or arms, loss of sensation (including blindness),[3] and/or bladder and bowel dysfunction.[4]

Devic's disease is now studied along a collection of similar diseases called "Neuromyelitis optica spectrum diseases".[5] Some cases of this spectrum resemble multiple sclerosis (MS) in several ways, but require a different course of treatment for optimal results.[4]

In 2004, NMO-IgG (currently known as Anti-AQP IgG) was first described[6] leading to the distinction between positive and negative cases.

In Anti-AQP positive variants, CNS astrocytes, which are the basis for the glymphatic system [7] are the target of the autoimmune attack. NMO-IgG-negative cases are less understood. It seems currently that astrocytes are spared in these IgG negative cases.[8]

Signs and symptoms

The main symptoms of Devic's disease are loss of vision and spinal cord function. Optic neuritis may manifest as visual impairment with decreased visual acuity, although visual field defects, or loss of color vision may occur in isolation or prior to formal loss of acuity. Spinal cord dysfunction can lead to muscle weakness, reduced sensation, or loss of bladder and bowel control.[9] The typical patient has an acute and severe spastic weakness of the legs (paraparesis) or all four limbs (quadriparesis) with sensory signs, often accompanied by loss of bladder control.

Diagnosis

The Mayo Clinic proposed a revised set of criteria for diagnosis of Devic's disease in 2006. Those new guidelines require two absolute criteria plus at least two of three supportive criteria.[10] In 2015 a new review was published by an international panel[5] refining the previous clinical case definition but leaving the main criteria unmodified:

Absolute criteria:

  1. Optic neuritis
  2. Acute myelitis

Supportive criteria:

  1. Brain MRI not meeting criteria for MS at disease onset
  2. Spinal cord MRI with contiguous T2-weighted signal abnormality extending over three or more vertebral segments, indicating a relatively large lesion in the spinal cord
  3. NMO-IgG seropositive status (The NMO-IgG test checks the existence of antibodies against the aquaporin 4 antigen.)

Variants

After the development of the NMO-IgG test, the spectrum of disorders comprising Devic's disease was expanded. The spectrum is now believed to consist of:

Whether Devic's disease is a distinct disease or part of the wide spectrum of multiple sclerosis is debated.[16] Devic's disease differs in that it usually has more severe sequelae after an acute episode than standard MS, MS infrequently presents as transverse myelitis, and oligoclonal bands in the CSF, as well as white matter lesions on brain MRI, are uncommon in Devic's disease, but occur in over 90% of MS patients.[17]

Recently, AQP4 has been found to distinguish standard multiple sclerosis from neuromyelitis optica, but as MS is a heterogeneous condition,[18] and some MS cases are reported to be Kir4.1 channelopathies[19] (autoimmunity against the potassium channels) it is still possible to consider NMO as part of the MS spectrum. Besides, some NMO-AQP(-) variants are not astrocytopathic, but demyelinating.[20]

Tumefactive lesions

Tumefactive demyelinating lesions in NMO are not usual, but they have been reported to appear in several cases mistakenly treated with interferon beta.[21]

Differential diagnosis

AQP4-Ab-negative NMO presents problems for diagnosis. The behavior of the oligoclonal bands respect MS can help to establish a more accurate diagnosis. Oligoclonal bands in NMO are rare and they tend to disappear after the attacks, while in MS they are nearly always present and persistent.[22]

Pathophysiology

Causes

Devic's disease has been associated with many systemic diseases, based on anecdotal evidence of some Devic's disease patients with a comorbid condition. Such conditions include: collagen vascular diseases, autoantibody syndromes, infections with varicella-zoster virus, Epstein-Barr virus, and HIV, and exposure to clioquinol and antituberculosis drugs.[23]

The discovery of NMO-IgG has opened a new way into the research for the causes. Currently two principal causes are accepted:

About the presence of NMO-IgG, some researchers have pointed out that some other cases could be paraneoplastic.[26] It seems also clear that lupus can produce NMO-IgG autoantibodies sometimes, leading to some cases of lupus-derived NMO.[27]

In any case, the IgG generation is produced mainly intrathecally.[28]

Mechanism

Devic's disease is similar to MS in that the body's immune system attacks the myelin surrounding nerve cells. Unlike standard MS, the attacks are not believed to be mediated by the immune system's T cells, but rather by antibodies called NMO-IgG, or simply NMO antibodies. These antibodies target the protein aquaporin 4 in the cell membranes of astrocytes which acts as a channel for the transport of water across the cell membrane.[4] Aquaporin 4 is found in the processes of the astrocytes that surround the blood–brain barrier, a system responsible for preventing substances in the blood from crossing into the brain. The blood–brain barrier is weakened in Devic's disease, but it is currently unknown how the NMO-IgG immune response leads to demyelination.

Most research into the pathology of Devic's disease has focused on the spinal cord. The damage can range from inflammatory demyelination to necrotic damage of the white and grey matters. The inflammatory lesions in Devic's disease have been classified as type II lesions (complement-mediated demyelinization), but they differ from MS pattern II lesions in their prominent perivascular distribution. Therefore, the pattern of inflammation is often quite distinct from that seen in MS.[4][29]

Treatment

Chemical structure of methylprednisolone, which is used to treat attacks

Currently, there is no cure for Devic's disease, but symptoms can be treated. Some patients recover, but many are left with impairment of vision and limbs, which can be severe.

Attacks

Attacks are treated with short courses of high dosage intravenous corticosteroids such as methylprednisolone IV.

Plasmapheresis can be an effective treatment[12] when attacks progress or do not respond to corticosteroid treatment. Clinical trials for these treatments contain very small numbers, and most are uncontrolled, though some report high success percentage.[30]

Secondary prevention

No controlled trials have established the effectiveness of treatments for the prevention of attacks. Many clinicians agree that long term immunosuppression is required to reduce the frequency and severity of attacks, while others argue the exact opposite.[31] Commonly used immunosuppressant treatments include azathioprine (Imuran) plus prednisone, mycophenolate mofetil plus prednisone, rituximab, mitoxantrone, intravenous immunoglobulin (IVIG), and cyclophosphamide.[12][32] The monoclonal antibody rituximab is under study.[33] In 2007, Devic's disease was reported to be responsive to glatiramer acetate[34] and to low-dose corticosteroids.[35]

Prognosis

Normally, some measure of improvement appears in a few weeks, but residual signs and disability may persist, sometimes severely.

The disease can be monophasic, i.e. a single episode with permanent remission. However, at least 85% of patients have a relapsing form of the disease with repeated attacks of transverse myelitis and/or optic neuritis. In patients with the monophasic form, the transverse myelitis and optic neuritis occur simultaneously or within days of each other. On the other hand, patients with the relapsing form are more likely to have weeks or months between the initial attacks, and to have better motor recovery after the initial transverse myelitis event. Relapses usually occur early, with about 55% of patients having a relapse in the first year and 90% in the first five years.[4]

It is possible that the relapsing form is related to the antiAQP4+ seropositive status and the monophasic form related to its absence[36] Unlike multiple sclerosis, Devic's disease rarely has a secondary progressive phase in which patients have increasing neurologic decline between attacks without remission. Instead, disabilities arise from the acute attacks.[4]

Approximately 20% of patients with monophasic Devic's disease have permanent visual loss, and 30% have permanent paralysis in one or both legs. Among patients with relapsing Devic's disease, 50% have paralysis or blindness within five years. In some patients (33% in one study), transverse myelitis in the cervical spinal cord resulted in respiratory failure and subsequent death. However, the spectrum of Devic's disease has widened due to improved diagnostic criteria, and the options for treatment have improved; as a result, researchers believe these estimates will be lowered.[4]

Epidemiology

The prevalence and incidence of Devic's disease has not been established, partly because the disease is underrecognized and often confused with MS.[4] Devic's disease is more common in women than men, with women comprising over two-thirds of patients and more than 80% of those with the relapsing form of the disease.[4]

A retrospective study found that prevalence of NMOsd was 1.5% inside a random sample of neurological patients, with a MS:NMOsd ratio of 42.7. Among 13 NMOsd patients, 77% had long spinal cord lesions, 38% had severe optic neuritis and 23% had brain or brainstem lesions. Only 56% had clinically definite NMO at follow-up.[37]

According to the Walton Centre in England, "NMO seems to be present across the world unlike MS, which has a higher incidence in temperate climates and white races. Africans and Asians especially in Far East may have a higher risk of NMO, although the exact incidence of this disease is unknown, making specific conclusions difficult". Although many people who have Devic's disease were initially misdiagnosed with MS, 35% of African Americans are often misdiagnosed with MS when they really have NMO.

Devic's disease is more common in Asians than Caucasians. In fact, Asian optic-spinal MS (which constitutes 30% of the cases of MS in Japan) has been suggested to be identical to Devic's disease (differences between optic-spinal and classic MS in Japanese patients). In the indigenous populations of tropical and subtropical regions, MS is rare, but when it appears, it often takes the form of optic-spinal MS.[38]

The majority of Devic's disease patients have no affected relatives, and it is generally regarded as a nonfamilial condition.[4]

Neuromyelitis optica spectrum disorders

Since the discovery of AQP4 autoantibody, it has been found that it appears also in patients with NMO-like symptoms that do not fulfill the clinical requirements to be diagnosed NMO (Recurrent and simultaneous optic nerve and spinal cord inflammation).[39]

The term NMOSD (NMO Spectrum Disorders) has been designed to allow incorporation of cases associated a non-AQP4 biomarkers.[5] Therefore it includes all the clinical variants due to anti-AQP4 plus other non-related but clinically similar syndromes like antiMOG associated encephalomyelitis. Some cases with MOG+ and AQP4+ antibodies have been found[40]

The collection of these condition has been named "neuromyelitis optica spectrum disorders" (NMSD) and they are expected to respond to the same treatments as standard NMO.[41] Some authors propose to use the name "autoimmune aquaporin-4 channelopathy" for these diseases,[24] while others prefer a more generic term "AQP4-astrocytopathy" that includes also problems in AQP4 with a non-autoimmune origin.[42]

History

Sir Thomas Clifford Allbutt

First reports on an association of spinal cord and optic nerve disorders appeared in the early 19th century.[43] However, only an 1870 report by Sir Thomas Clifford Allbutt created sustained interest of neurologists and ophthalmologists in this rare syndrome.[44] In 1894, Eugène Devic and his PhD student Fernand Gault described 16 patients who had lost vision in one or both eyes and within weeks developed severe spastic weakness of the limbs, loss of sensation and often bladder control. They recognized these symptoms were the result of inflammation of the optic nerve and spinal cord, respectively.[43][45][46]

Similar instances of optic neuritis and myelitis were reported, and many believed it constituted a distinct clinical entity. However, some patients had pathology in other parts of the brain, a feature which was more suggestive of acute disseminated encephalomyelitis or MS.

In 2004, Mayo Clinic researchers identified an unknown specific autoantibody[6] and in 2005 they identified the aquaporin 4 protein as the target of the disease, and developed a test to aid in the diagnosis of Devic's disease by detection of an antibody, NMO-IgG, in the blood.[7] Some patients with NMO may be seronegative for NMO-IgG, whilst some patients with NMO-IgG may still not fulfill clinical criteria for NMO thus serological testing is now an important part of the diagnostic procedure and seropositive and seronegative cases are described in a manner similar to myasthenia gravis. According to the Mayo Clinic report, this was the first time a molecular target had been identified for a type of demyelinating inflammatory disease.[47]

Research directions

Since the discovery of AQP-4 involvement, some research studies have focused on targeted treatment aimed at anti-aquaporin 4 antibodies. The most established method for antibody removal is plasmapheresis. A number of drugs are being studied: aquaporumab (non-pathogenic antibody blocker of AQP4-IgG binding), sivelestat (neutrophil elastase inhibitor), and eculizumab (complement inhibitor).[48]

There is little research into the primary causes of the Anti-AQP4 auto-antibodies. It has been noticed that some cases could be paraneoplastic.[26]

MOG-associated NMO

About the AQP4-negative variants, they are expected to be also heterogeneus. Six different patterns of damage have been reported in NMO, opening the possibility of having five different types of AQP4-negative variants.[49]

Currently, the most promising biomarker for diagnosis is the presence of the anti-MOG autoantibody, which together with the anti-AQP4 can classify the NMO cases in four classes, according to the presence or absence of any of the two antibodies.[50]

Besides MOG antibodies are currently considered mostly absent in multiple sclerosis.[51] Therefore, it can be said that anti-MOG is a group contained inside AQP-Negative NMO.[15]

The clinical course and the response to therapy is different for these groups, showing a better prognosis those with NMO-Ab(−)/MOG-Ab(−) group, and worse prognosis those in (NMO-Ab(+)/MOG-Ab(+).[50] The MOG-related neuromyelitis optica can be radiologically identified by the conus involvement. Myelin-oligodendrocyte glycoprotein antibody–positive patients were more likely to have conus involvement on spinal magnetic resonance imaging.[52]

Other AQP4-negative variants

Finally, other two proteins under study are Connexin 43 and anti-AQP1 though, as of 2015, there are only initial reports about the involvement of these proteins[39][42]

The group AQP+/MOG+ is very small and it can be considered a coincidence of two independent problems in the same person. Assuming these cases could be verified, currently five different kinds of NMO are being considered:

See also

References

  1. ↑ Lucchinetti, Claudia F.; Guo, Yong; Popescu, Bogdan F. Gh.; Fujihara, Kazuo; Itoyama, Yasuto; Misu, Tatsuro (January 2014). "The Pathology of an Autoimmune Astrocytopathy: Lessons Learned from Neuromyelitis Optica". Brain Pathology 24 (1): 83–97. doi:10.1111/bpa.12099. PMC 3905574. PMID 24345222.
  2. ↑ Pittock SJ, Weinshenker BG, Lucchinetti CF, Wingerchuk DM, Corboy JR, Lennon VA (2006). "Neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expression". Arch. Neurol. 63 (7): 964–968. doi:10.1001/archneur.63.7.964. PMID 16831965.
  3. ↑ "neuromyelitis optica" at Dorland's Medical Dictionary
  4. 1 2 3 4 5 6 7 8 9 10 Wingerchuk, DM (2006). "Neuromyelitis optica". The International MS Journal 13 (2): 42–50. PMID 16635421.
  5. 1 2 3 Wingerchuk, D. M.; Banwell, B.; Bennett, J. L.; Cabre, P.; Carroll, W.; Chitnis, T.; de Seze, J.; Fujihara, K.; Greenberg, B.; Jacob, A.; Jarius, S.; Lana-Peixoto, M.; Levy, M.; Simon, J. H.; Tenembaum, S.; Traboulsee, A. L.; Waters, P.; Wellik, K. E.; Weinshenker, B. G. (19 June 2015). "International consensus diagnostic criteria for neuromyelitis optica spectrum disorders". Neurology 85 (2): 177–189. doi:10.1212/WNL.0000000000001729. PMC 4515040. PMID 26092914.
  6. 1 2 Lennon VA, Wingerchuk DM, Kryzer TJ, et al. (2004). "A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis". Lancet 364 (9451): 2106–2112. doi:10.1016/S0140-6736(04)17551-X. PMID 15589308.
  7. 1 2 Lennon VA, Kryzer TJ, Pittock SJ, Verkman AS, Hinson SR (2005). "IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel". J. Exp. Med. 202 (4): 473–477. doi:10.1084/jem.20050304. PMC 2212860. PMID 16087714.
  8. ↑ Ikeda, K; Kiyota, N; Kuroda, H; Sato, DK; Nishiyama, S; Takahashi, T; Misu, T; Nakashima, I; Fujihara, K; Aoki, M (April 2015). "Severe demyelination but no astrocytopathy in clinically definite neuromyelitis optica with anti-myelin-oligodendrocyte glycoprotein antibody.". Multiple sclerosis (Houndmills, Basingstoke, England) 21 (5): 656–9. doi:10.1177/1352458514551455. PMID 25257613.
  9. ↑ Mayo Clinic. "Devic's Disease Symptoms". Archived from the original on 2008-01-02. Retrieved 2008-03-11.
  10. ↑ Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG (2006). "Revised diagnostic criteria for neuromyelitis optica". Neurology 66 (10): 1485–1489. doi:10.1212/01.wnl.0000216139.44259.74. PMID 16717206.
  11. ↑ Li Y, Xie P, Lv F, et al. (2008). "Brain magnetic resonance imaging abnormalities in neuromyelitis optica". Acta Neurol. Scand. 0 (4): 218–25. doi:10.1111/j.1600-0404.2008.01012.x. PMID 18384459.
  12. 1 2 3 Wingerchuk, Dean (2006). "Neuromyelitis Optica (Devic's Syndrome)" (PDF). 2006 Rare Neuroimmunologic Disorders Symposium. Retrieved 2007-01-05.
  13. ↑ Fujihara, K; Leite, MI (11 June 2013). "Seronegative NMO: a sensitive AQP4 antibody test clarifies clinical features and next challenges.". Neurology 80 (24): 2176–7. doi:10.1212/WNL.0b013e318296ea22. PMID 23658387.
  14. ↑ Marignier, R; Bernard-Valnet, R; Giraudon, P; Collongues, N; Papeix, C; Zéphir, H; Cavillon, G; Rogemond, V; Casey, R; Frangoulis, B; De Sèze, J; Vukusic, S; Honnorat, J; Confavreux, C; NOMADMUS Study, Group (11 June 2013). "Aquaporin-4 antibody-negative neuromyelitis optica: distinct assay sensitivity-dependent entity.". Neurology 80 (24): 2194–200. doi:10.1212/WNL.0b013e318296e917. PMID 23658379.
  15. 1 2 Pröbstel, AK; Rudolf, G; Dornmair, K; Collongues, N; Chanson, JB; Sanderson, NS; Lindberg, RL; Kappos, L; de Seze, J; Derfuss, T (8 March 2015). "Anti-MOG antibodies are present in a subgroup of patients with a neuromyelitis optica phenotype.". Journal of neuroinflammation 12 (1): 46. doi:10.1186/s12974-015-0256-1. PMC 4359547. PMID 25889963.
  16. ↑ Saida T (2008). "Overview of MS: proposal of new MS definition/classification and review of the results of recent clinical trials". Nippon Rinsho (abstract) 66 (6): 1081–6. PMID 18540351.
  17. ↑ Pearce JM (2005). "Neuromyelitis optica". Spinal Cord (abstract) 43 (11): 631–634. doi:10.1038/sj.sc.3101758. PMID 15968305.
  18. ↑ Lassmann, H; Brück, W; Lucchinetti, C (2001). "Heterogeneity of multiple sclerosis pathogenesis: Implications for diagnosis and therapy". Trends in molecular medicine 7 (3): 115–21. doi:10.1016/s1471-4914(00)01909-2. PMID 11286782.
  19. ↑ Schneider, R (2013). "Autoantibodies to Potassium Channel KIR4.1 in Multiple Sclerosis". Frontiers in Neurology 4: 125. doi:10.3389/fneur.2013.00125. PMC 3759297. PMID 24032025.
  20. ↑ Kurosawa, K; Fujihara, K (November 2014). "[Clinical concept, etiology and pathology of neuromyelitis optica].". Nihon rinsho. Japanese journal of clinical medicine 72 (11): 1897–902. PMID 25518368.
  21. ↑ Harmel, J; Ringelstein, M; Ingwersen, J; Mathys, C; Goebels, N; Hartung, HP; Jarius, S; Aktas, O (17 December 2014). "Interferon-β-related tumefactive brain lesion in a Caucasian patient with neuromyelitis optica and clinical stabilization with tocilizumab.". BMC neurology 14: 247. doi:10.1186/s12883-014-0247-3. PMID 25516429.
  22. ↑ Bergamaschi, R; Tonietti, S; Franciotta, D; Candeloro, E; Tavazzi, E; Piccolo, G; Romani, A; Cosi, V (1 February 2004). "Oligoclonal bands in Devic's neuromyelitis optica and multiple sclerosis: differences in repeated cerebrospinal fluid examinations". Multiple Sclerosis 10 (1): 2–4. doi:10.1191/1352458504ms988oa. PMID 14760945.
  23. ↑ Cree BA, Goodin DS, Hauser SL (2002). "Neuromyelitis optica". Seminars in neurology 22 (2): 105–122. doi:10.1055/s-2002-36534. PMID 12524556.
  24. 1 2 Pittock, Sean J.; Lucchinetti, Claudia F. (June 2015). "Neuromyelitis optica and the evolving spectrum of autoimmune aquaporin-4 channelopathies: a decade later". Annals of the New York Academy of Sciences. doi:10.1111/nyas.12794. PMID 26096370.
  25. 1 2 Spadaro, Melania; Gerdes, Lisa Ann; Mayer, Marie C.; Ertl-Wagner, Birgit; Laurent, Sarah; Krumbholz, Markus; Breithaupt, Constanze; Högen, Tobias; Straube, Andreas; Giese, Armin; Hohlfeld, Reinhard; Lassmann, Hans; Meinl, Edgar; Kümpfel, Tania (March 2015). "Histopathology and clinical course of MOG-antibody-associated encephalomyelitis". Annals of Clinical and Translational Neurology 2 (3): 295–301. doi:10.1002/acn3.164. PMC 4369279. PMID 25815356.
  26. 1 2 Iorio, R.; Rindi, G.; Erra, C.; Damato, V.; Ferilli, M.; Sabatelli, M. (25 February 2015). "Neuromyelitis optica spectrum disorder as a paraneoplastic manifestation of lung adenocarcinoma expressing aquaporin-4". Multiple Sclerosis Journal 21 (6): 791–794. doi:10.1177/1352458515572241. PMID 25716881.
  27. ↑ Kovacs, K. T.; Kalluri, S. R.; Boza-Serrano, A.; Deierborg, T.; Csepany, T.; Simo, M.; Rokusz, L.; Miseta, A.; Alcaraz, N.; Czirjak, L.; Berki, T.; Molnar, T.; Hemmer, B.; Illes, Z. (29 October 2015). "Change in autoantibody and cytokine responses during the evolution of neuromyelitis optica in patients with systemic lupus erythematosus: A preliminary study". Multiple Sclerosis Journal. doi:10.1177/1352458515613165. PMID 26514978.
  28. ↑ Kowarik, Markus C; Dzieciatkowska, Monika; Wemlinger, Scott; Ritchie, Alanna M; Hemmer, Bernhard; Owens, Gregory P; Bennett, Jeffrey L (2015). "The cerebrospinal fluid immunoglobulin transcriptome and proteome in neuromyelitis optica reveals central nervous system-specific B cell populations". Journal of Neuroinflammation 12 (1): 19. doi:10.1186/s12974-015-0240-9. PMC 4323273. PMID 25626447.
  29. ↑ Lucchinetti CF, Mandler RN, McGavern D, et al. (2002). "A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica". Brain 125 (Pt 7): 1450–1461. doi:10.1093/brain/awf151. PMID 12076996.
  30. ↑ Morgan, Shanna M.; Zantek, Nicole D.; Carpenter, Adam F. (June 2014). "Therapeutic plasma exchange in neuromyelitis optica: A case series". Journal of Clinical Apheresis 29 (3): 171–177. doi:10.1002/jca.21304. PMID 24136389.
  31. ↑ Poser CM, Brinar VV (2007). "Disseminated encephalomyelitis and multiple sclerosis: two different diseases – a critical review". Acta Neurol. Scand. 116 (4): 201–206. doi:10.1111/j.1600-0404.2007.00902.x. PMID 17824894.
  32. ↑ Weinstock-Guttman B, Ramanathan M, Lincoff N, et al. (2006). "Study of mitoxantrone for the treatment of recurrent neuromyelitis optica (Devic disease)". Arch. Neurol. 63 (7): 957–963. doi:10.1001/archneur.63.7.957. PMID 16831964.
  33. ↑ Matiello M, Jacob A, Wingerchuk DM, Weinshenker BG (2007). "Neuromyelitis optica". Current Opinion in Neurology 20 (3): 255–260. doi:10.1097/WCO.0b013e32814f1c6b. PMID 17495617.
  34. ↑ Gartzen K, Limmroth V, Putzki N (2007). "Relapsing neuromyelitis optica responsive to glatiramer acetate treatment". Eur. J. Neurol. 14 (6): e12–3. doi:10.1111/j.1468-1331.2007.01807.x. PMID 17539924.
  35. ↑ Watanabe S, Misu T, Miyazawa I, et al. (2007). "Low-dose corticosteroids reduce relapses in neuromyelitis optica: a retrospective analysis". Multiple Sclerosis 13 (8): 968–74. doi:10.1177/1352458507077189. PMID 17623727.
  36. ↑ Ketelslegers, I. A.; Modderman, P. W.; Vennegoor, A.; Killestein, J.; Hamann, D.; Hintzen, R. Q. (9 August 2011). "Antibodies against aquaporin-4 in neuromyelitis optica: distinction between recurrent and monophasic patients". Multiple Sclerosis Journal 17 (12): 1527–1530. doi:10.1177/1352458511412995. PMID 21828202.
  37. ↑ Bizzoco, Elisa; Lolli, Francesco; Repice, Anna Maria; Hakiki, Bahia; Falcini, Mario; Barilaro, Alessandro; Taiuti, Rosanna; Siracusa, Gianfranco; Amato, Maria Pia; Biagioli, Tiziana; Lori, Silvia; Moretti, Marco; Vinattieri, Annalisa; Nencini, Patrizia; Massacesi, Luca; Matà, Sabrina (28 May 2009). "Prevalence of neuromyelitis optica spectrum disorder and phenotype distribution". Journal of Neurology 256 (11): 1891–1898. doi:10.1007/s00415-009-5171-x. PMID 19479168.
  38. ↑ Cabre P, Signate A, Olindo S, et al. (2005). "Role of return migration in the emergence of multiple sclerosis in the French West Indies". Brain 128 (Pt 12): 2899–2910. doi:10.1093/brain/awh624. PMID 16183661.
  39. 1 2 Masaki, K; Suzuki, SO; Matsushita, T; Matsuoka, T; Imamura, S; Yamasaki, R; Suzuki, M; Suenaga, T; Iwaki, T; Kira, J (2013). "Connexin 43 astrocytopathy linked to rapidly progressive multiple sclerosis and neuromyelitis optica.". PloS one 8 (8): e72919. doi:10.1371/journal.pone.0072919. PMID 23991165.
  40. ↑ Franziska Di Pauli, Fulminant demyelinating encephalomyelitis. Insights from antibody studies and neuropathology, doi: http://dx.doi.org/10.1212/NXI.0000000000000175, Neurol Neuroimmunol Neuroinflamm December 2015 vol. 2 no. 6 e175
  41. ↑ Fujihara, K.; Sato, D. K. (30 August 2013). "AQP4 antibody serostatus: Is its luster being lost in the management and pathogenesis of NMO?". Neurology 81 (14): 1186–1188. doi:10.1212/WNL.0b013e3182a6cc23. PMID 23997154.
  42. 1 2 Masaki, Katsuhisa (October 2015). "Early disruption of glial communication via connexin gap junction in multiple sclerosis, Baló's disease and neuromyelitis optica". Neuropathology 35 (5): 469–480. doi:10.1111/neup.12211. PMID 26016402.
  43. 1 2 Jarius, Sven; Wildemann, Brigitte (2013). "The history of neuromyelitis optica". Journal of Neuroinflammation 10 (1): 8. doi:10.1186/1742-2094-10-8. PMID 23320783.
  44. ↑ Jarius, S.; Wildemann, B. (11 July 2012). "On the contribution of Thomas Clifford Allbutt, F.R.S., to the early history of neuromyelitis optica". Journal of Neurology 260 (1): 100–104. doi:10.1007/s00415-012-6594-3. PMID 22782261.
  45. ↑ Devic E (1894). "Myélite subaiguë compliquée de névrite optique". Bull Med (in French) 8: 1033.
  46. ↑ T. Jock Murray (2005). Multiple Sclerosis: The History of a Disease. New York: Demos Medical Publishing. ISBN 1-888799-80-3.
  47. ↑ "Devic's Disease Research – Mayo Clinic". Retrieved 2007-11-22.
  48. ↑ Papadopoulos MC, Verkman AS (June 2012). "Aquaporin 4 and neuromyelitis optica". Lancet Neurol 11 (6): 535–44. doi:10.1016/S1474-4422(12)70133-3. PMC 3678971. PMID 22608667.
  49. ↑ Misu, Tatsuro; Höftberger, Romana; Fujihara, Kazuo; Wimmer, Isabella; Takai, Yoshiki; Nishiyama, Shuhei; Nakashima, Ichiro; Konno, Hidehiko; Bradl, Monika; Garzuly, Ferenc; Itoyama, Yasuto; Aoki, Masashi; Lassmann, Hans (12 April 2013). "Presence of six different lesion types suggests diverse mechanisms of tissue injury in neuromyelitis optica". Acta Neuropathologica 125 (6): 815–827. doi:10.1007/s00401-013-1116-7. PMC 3661909. PMID 23579868.
  50. 1 2 Kezuka, Takeshi; Usui, Yoshihiko; Yamakawa, Naoyuki; Matsunaga, Yoshimichi; Matsuda, Ryusaku; Masuda, Masayuki; Utsumi, Hiroya; Tanaka, Keiko; Goto, Hiroshi (June 2012). "Relationship Between NMO-Antibody and Anti–MOG Antibody in Optic Neuritis". Journal of Neuro-Ophthalmology 32 (2): 107–110. doi:10.1097/WNO.0b013e31823c9b6c. PMID 22157536.
  51. ↑ Ketelslegers, I. A.; Van Pelt, D. E.; Bryde, S.; Neuteboom, R. F.; Catsman-Berrevoets, C. E.; Hamann, D.; Hintzen, R. Q. (6 February 2015). "Anti-MOG antibodies plead against MS diagnosis in an Acquired Demyelinating Syndromes cohort". Multiple Sclerosis Journal 21 (12): 1513–1520. doi:10.1177/1352458514566666. PMID 25662345.
  52. ↑ Kitley, Joanna; Waters, Patrick; Woodhall, Mark; Leite, M. Isabel; Murchison, Andrew; George, Jithin; Küker, Wilhelm; Chandratre, Saleel; Vincent, Angela; Palace, Jacqueline (1 March 2014). "Neuromyelitis Optica Spectrum Disorders With Aquaporin-4 and Myelin-Oligodendrocyte Glycoprotein Antibodies". JAMA Neurology 71 (3): 276. doi:10.1001/jamaneurol.2013.5857. PMID 24425068.

External links

This article is issued from Wikipedia - version of the Saturday, April 16, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.